Clozapine therapy for Parkinson's disease and other movement disorders.
Recent research on the role of clozapine in the treatment of Parkinson's disease and other movement disorders is discussed. Most clinical trials have shown resolution of or improvement in psychotic symptoms accompanying Parkinson's disease without worsening of parkinsonian symptoms. Adverse effects appear to be mild at dosages of < 100 mg/day; sedation is the most frequent problem. Most of these studies have serious limitations, however; until better studies have been completed, the decision to use clozapine for Parkinson's disease-related psychosis should be made on a case-by-case basis, with thorough evaluation of risks, benefits, and other therapeutic options. Some patients with Parkinson's disease have shown improvement in tremor and other abnormal movements when given clozapine. Clozapine cannot be recommended for treating tardive dyskinesia on the basis of the research done so far; some trials show dramatic resolution of symptoms, others no benefit. Anticholinergics or dopamine-reuptake inhibitors should be considered before clozapine is given to patients with tardive dyskinesia because of clozapine's potential for serious adverse effects. A few patients with Huntington's disease have responded to clozapine, but again no conclusions can be drawn. Clozapine appears to offer no real advantage over haloperidol for treating choreiform movements in Huntington's disease. The frequency of tics in Tourette's syndrome does not seem to be reduced by clozapine. Clozapine has shown some efficacy as a treatment for psychosis and abnormal movements in Parkinson's disease. Results have been less promising for other movement disorders. Further study in larger populations is needed before any definitive conclusions about clozapine's place in movement disorder therapy can be made.
Department of Pharmacy Practice, Rutgers, State University of New Jersey (RSUNJ), Piscataway 08855.
C
C
Pfeiffer
M L
ML
Wagner
D002986:Clinical Trials as Topic; D003024:Clozapine / Q000627:therapeutic use*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D009069:Movement Disorders / Q000150:complications / Q000188:drug therapy; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D005879:Tourette Syndrome / Q000188:drug therapy
D003024:Clozapine